Regeneron Product REGN-EB3 Saving Lives
Regeneron (REGN) announced that an independent monitoring board ended its investigational product REGN-EB3 trial after reviewing interim mortality data from 499 patients. REGN-EB3 was found superior to rival therapy from Mapp Biopharmaceuticals (MAPP) in saving the lives in . . .
This content is for paid subscribers.
Today’s Highlights August 13, 2019